Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Abstract The hypomethylating agents (HMAs) azacitidine and decitabine have been the de facto standard of care for patients with acute myeloid leukemia (AML) who are unfit for intensive therapy. Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 2263 older a...
Guardat en:
| Autors principals: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | anglès |
| Publicat: |
2020
|
| Accés en línia: | https://doi.org/10.1182/bloodadvances.2020001779 https://ashpublications.org/bloodadvances/article-pdf/4/10/2192/1731682/advancesadv2020001779.pdf |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|